HERON THERAPEUTICS, INC. /DE/ Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature
HERON THERAPEUTICS, INC. /DE/ (HRTX) reported Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature of $230.00 thousand for the 12-month period ending 2021-12-31, per its 10-K filed 2023-03-29.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature · last filed 2023-03-29
- HERON THERAPEUTICS, INC. /DE/ adjustments to additional paid in capital, convertible debt with conversion feature for the quarter ending 2021-06-30 was $116.00K, a 6.42% increase year-over-year.
- HERON THERAPEUTICS, INC. /DE/ adjustments to additional paid in capital, convertible debt with conversion feature for the quarter ending 2021-03-31 was $114.00K, a 5.56% increase year-over-year.
- HERON THERAPEUTICS, INC. /DE/ adjustments to additional paid in capital, convertible debt with conversion feature for the quarter ending 2020-09-30 was $111.00K, a 5.71% increase year-over-year.
- HERON THERAPEUTICS, INC. /DE/ adjustments to additional paid in capital, convertible debt with conversion feature for the quarter ending 2020-06-30 was $109.00K, a 5.83% increase year-over-year.
- HERON THERAPEUTICS, INC. /DE/ adjustments to additional paid in capital, convertible debt with conversion feature for fiscal 2021 was $230.00K, a 47.73% decline from fiscal 2020.
- HERON THERAPEUTICS, INC. /DE/ adjustments to additional paid in capital, convertible debt with conversion feature for fiscal 2020 was $440.00K, a 5.77% increase from fiscal 2019.
- HERON THERAPEUTICS, INC. /DE/ adjustments to additional paid in capital, convertible debt with conversion feature for fiscal 2019 was $416.00K, a 6.12% increase from fiscal 2018.
- HERON THERAPEUTICS, INC. /DE/ adjustments to additional paid in capital, convertible debt with conversion feature for fiscal 2018 was $392.00K, a 6.23% increase from fiscal 2017.
| Period end | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 3 month | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 6 month | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 9 month | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 12 month |
|---|---|---|---|---|
| 2021-12-31 | $230.00K 10-K · filed 2023-03-29 | |||
| 2021-06-30 | $116.00K 10-Q · filed 2022-11-08 | $230.00K derived: sum of 2 quarters · filed 2022-11-08 | ||
| 2021-03-31 | $114.00K 10-Q · filed 2022-11-08 | |||
| 2020-12-31 | $440.00K 10-K · filed 2022-02-28 | |||
| 2020-09-30 | $111.00K 10-Q · filed 2021-11-03 | $220.00K derived: sum of 2 quarters · filed 2021-11-03 | $328.00K derived: sum of 3 quarters · filed 2021-11-03 | |
| 2020-06-30 | $109.00K 10-Q · filed 2021-11-03 | $217.00K derived: sum of 2 quarters · filed 2021-11-03 | ||
| 2020-03-31 | $108.00K 10-Q · filed 2021-11-03 | |||
| 2019-12-31 | $416.00K 10-K · filed 2022-02-28 | |||
| 2019-09-30 | $105.00K 10-Q · filed 2020-11-05 | $208.00K derived: sum of 2 quarters · filed 2020-11-05 | $310.00K derived: sum of 3 quarters · filed 2020-11-05 | |
| 2019-06-30 | $103.00K 10-Q · filed 2020-11-05 | $205.00K derived: sum of 2 quarters · filed 2020-11-05 | ||
| 2019-03-31 | $102.00K 10-Q · filed 2020-11-05 | |||
| 2018-12-31 | $392.00K 10-K · filed 2021-02-24 | |||
| 2018-09-30 | $99.00K 10-Q · filed 2019-11-12 | $196.00K derived: sum of 2 quarters · filed 2019-11-12 | $292.00K derived: sum of 3 quarters · filed 2019-11-12 | |
| 2018-06-30 | $97.00K 10-Q · filed 2019-11-12 | $193.00K derived: sum of 2 quarters · filed 2019-11-12 | ||
| 2018-03-31 | $96.00K 10-Q · filed 2019-11-12 | |||
| 2017-12-31 | $369.00K 10-K · filed 2020-03-02 | |||
| 2016-12-31 | $348.00K 10-K · filed 2019-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| Lite Strategy, Inc. (LITS) | United States | $0.049B |